SAB Biotherapeutics To Present New Data At ISIRV OPTIONS XI Conference On SAB-176 Phase 2a Influenza Trial September 29 And SAB-185’s Effectiveness Against Multiple COVID-19 Variants September 27



SIOUX FALLS, S.D., Sept. 23, 2022 (GLOBE NEWSWIRE) — SAB Biotherapeutics (NASDAQ:SABS), (“SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, announced today that the Company will present new data on its fully-human polyclonal antibody platform’s ability to maintain its efficacy against multiple variants of several highly mutating viruses at the Options for Control of Influenza (OPTIONS XI) conference, which is hosted by the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) in Belfast, Northern Ireland, from Sept. 26-29, 2022.

SAB will conduct an oral presentation, titled “Efficacy and Safety of SAB-176, a Novel Anti-Type A and B Influenza Immunotherapeutic: A Phase 2a, Randomized, Double-Blind Trial in H1N1 Challenged Adults,” on Thursday, Sept. 29, at 11: 24 AM BST.

Additionally, SAB will present a poster, titled “Transchromosomic Bovine-Derived Human Anti-SARS-CoV-2 Polyclonal Antibodies Protect hACE2 Transgenic Syrian Hamsters Against Multiple SARS CoV-2 Variants,” on Tuesday, Sept. 27, from 5:30-7 PM BST.

“We look forward to highlighting the power of polyclonal antibodies to neutralize highly mutating viruses and the differentiation of SAB’s novel therapeutic products at the upcoming ISIRV conference,” said Eddie Sullivan, co-founder, President, and Chief Executive Officer of SAB.

To view the OPTIONS XI program online, please visit:

Related Posts